Theolytics
PrivateLast Round
Grant
Mar 4, 2026
Total Funding Raised
$21.11M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Theolytics is a biotechnology company that develops oncolytic immunotherapies using a proprietary phenotypic screening platform to target and destroy cancer cells.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Theolytics Comparables
Compare Theolytics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| TILT Biotherapeutics | 90% | |
| Accession Therapeutics Limited | 86% | |
| ORCA Therapeutics | 84% |
Theolytics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Mar 4, 2026 | ||||
| Grant | Sep 2, 2024 | ||||
| VC Round | Apr 17, 2024 | ||||
| Grant | Jun 1, 2022 | ||||
| Series A Extension | Jul 8, 2021 | ||||
Series A | Jan 7, 2021 |
Key People
Founding team and executive leadership
Theolytics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovate UK | Grant |
| Epidarex Capital | VC Round, Series A Extension, Series A |
| Oxford Science Enterprises | VC Round, Series A, Seed |
| Taiho Ventures | VC Round, Series A Extension, Series A |
| M Ventures | VC Round, Series A Extension |
| UKRI Innovate UK | Grant |
| Horizon Europe | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 4, 2026
$9.3M raised in a grant round.
- Oct 1, 2025
Matilde Saggese, MD, appointed as new CMO.
Recent news
Latest coverage and updates
- is_developingSep 16, 2026
Theolytics will develop targeted adenoviral candidates on Nov 16th '26.
- is_developingJul 16, 2026
Theolytics was planning to develop oncolytic immunotherapies on Jul 16th '26.
- is_developingJul 14, 2026
Theolytics is developing oncolytic immunotherapies on Jul 14th '26.
Theolytics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Theolytics's valuation, stock price, and market status.
Is Theolytics a public or private company?
Theolytics is a private company.
What is the current stock price of Theolytics?
Theolytics is a private company with no public stock price. No recent secondary market data is available.
How much is Theolytics worth (valuation)?
Valuation information for Theolytics is not publicly available.
Can I buy Theolytics stock?
Theolytics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Theolytics's last funding round?
Theolytics's most recent funding round was Grant on March 4, 2026.
Who are the main investors in Theolytics?
Key investors in Theolytics include Epidarex Capital, Oxford Science Enterprises, Taiho Ventures, Oxford Science Enterprises, Sound Bioventures.
Will Theolytics IPO soon?
No public IPO plans have been announced for Theolytics.
How can I track Theolytics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Theolytics's secondary market activity and sign up for updates.